Literature DB >> 24460976

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Molly H Jenkins1, Shannon M Steinberg, Matthew P Alexander, Jan L Fisher, Marc S Ernstoff, Mary Jo Turk, David W Mullins, Constance E Brinckerhoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24460976      PMCID： PMC3988244          DOI： 10.1111/pcmr.12220

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  35 in total

1.  Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Authors:  Alexander M Menzies; Lauren E Haydu; Lydia Visintin; Matteo S Carlino; Julie R Howle; John F Thompson; Richard F Kefford; Richard A Scolyer; Georgina V Long
Journal:  Clin Cancer Res       Date:  2012-04-24       Impact factor: 12.531

2.  Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro.

Authors:  J Eberle; M Wagner; S MacNeil
Journal:  Pigment Cell Res       Date:  1998-06

3.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

4.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors:  Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-28       Impact factor: 11.205

5.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells.

Authors:  M P Ashley; I Kotlarski
Journal:  Cell Immunol       Date:  1986-08       Impact factor: 4.868

7.  Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance.

Authors:  S H Leveson; J H Howell; N S Paolini; M H Tan; E D Holyoke; M H Goldrosen
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

Review 9.  Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer.

Authors:  Sarah M Eck; Jessica S Blackburn; Adam C Schmucker; Peter S Burrage; Constance E Brinckerhoff
Journal:  J Autoimmun       Date:  2009-10-01       Impact factor: 7.094

10.  A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.

Authors:  J S Blackburn; I Liu; C I Coon; C E Brinckerhoff
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867
View more
  37 in total

1.  Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors.

Authors:  Jessica L F Teh; Dan A Erkes; Phil F Cheng; Manoela Tiago; Nicole A Wilski; Conroy O Field; Inna Chervoneva; Mitch P Levesque; Xiaowei Xu; Reinhard Dummer; Andrew E Aplin
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

2.  The β-catenin/YAP signaling axis is a key regulator of melanoma-associated fibroblasts.

Authors:  Tianyi Liu; Linli Zhou; Kun Yang; Kentaro Iwasawa; Ana Luisa Kadekaro; Takanori Takebe; Thomas Andl; Yuhang Zhang
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

3.  Elevated cyclic AMP levels promote BRAFCA/Pten-/- mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.

Authors:  Carlos I Rodríguez; Edgardo Castro-Pérez; B Jack Longley; Vijayasaradhi Setaluri
Journal:  Cancer Lett       Date:  2017-11-24       Impact factor: 8.679

4.  PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.

Authors:  Dan A Erkes; Sheera R Rosenbaum; Conroy O Field; Inna Chervoneva; Jessie Villanueva; Andrew E Aplin
Journal:  Pigment Cell Melanoma Res       Date:  2019-12-11       Impact factor: 4.693

5.  Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma.

Authors:  Lukas W Pfannenstiel; Corey McNeilly; Chaomei Xiang; Kai Kang; Claudia Marcella Diaz-Montero; Jennifer S Yu; Brian R Gastman
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

6.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

7.  EPAC-RAP1 Axis-Mediated Switch in the Response of Primary and Metastatic Melanoma to Cyclic AMP.

Authors:  Carlos I Rodríguez; Edgardo Castro-Pérez; Kirthana Prabhakar; Laura Block; B Jack Longley; Jaclyn A Wisinski; Michelle E Kimple; Vijayasaradhi Setaluri
Journal:  Mol Cancer Res       Date:  2017-08-29       Impact factor: 5.852

8.  Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.

Authors:  Qi Liu; Hongda Zhu; Karthik Tiruthani; Limei Shen; Fengqian Chen; Keliang Gao; Xueqiong Zhang; Lin Hou; Degeng Wang; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2018-01-31       Impact factor: 15.881

9.  Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.

Authors:  Qi Liu; Fengqian Chen; Lin Hou; Limei Shen; Xueqiong Zhang; Degeng Wang; Leaf Huang
Journal:  ACS Nano       Date:  2018-07-23       Impact factor: 15.881

10.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Authors:  Wanqiang Sheng; Martin W LaFleur; Thao H Nguyen; Sujun Chen; Ankur Chakravarthy; Jake Ryan Conway; Ying Li; Hao Chen; Henry Yang; Pang-Hung Hsu; Eliezer M Van Allen; Gordon J Freeman; Daniel D De Carvalho; Housheng Hansen He; Arlene H Sharpe; Yang Shi
Journal:  Cell       Date:  2018-06-21       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.